Abstract: Novel bacteriophages of Bacillus anthracis, the nucleic acids of its genome, nucleic acids comprising nucleotide sequences of open reading frames (ORFs) of its genome, and polypeptides encoded by the nucleic acids, are described. Therapeutic and diagnostic compositions, methods and kits related thereto are also provided.

Abstract: Compounds represented by Formula I and II, or pharmaceutically acceptable salts thereof: inhibit bacterial 2-epimerase and are useful anti-infective agents.

Abstract: An endopeptidase is described which shows specificity for cleavage of a LPXTG (SEQ ID NO: 1) motif found in the cell membranes of gram positive bacteria, having an apparent molecular weight of 14,000 daltons, having a pH optimum of about 7.5 to 10, being salt sensitive, being heavily glycosylated, rich in alanine, lacking aromatic amino acids, having a Km of 0.26 mM and having a backbone comprised of about 30% unknown amino acids, and containing carbohydrates that are essential for its activity. Methods of use and pharmaceutical compositions of this inhibitor are described.

Abstract: The full-length nucleic acid sequence of the C1 bacteriophage is disclosed in the present application. The specific regions of the C1 genome encoding the PlyC lysin have also been identified and sequenced. The invention relates to the pharmaceutical and diagnostic utility of these sequences and provides for development of pharmaceutical compositions for treating or preventing streptococcal infections in mammals, for compositions for decontamination of inanimate surfaces and for diagnosis of streptococcal infections.

Abstract: The present disclosure relates to bacteriophage lysins useful for the reduction of certain bacterial populations, including methods and compositions for the treatment of various bacterial infections. For example, bacteriophage lysins were isolated and shown to effectively kill various bacteria, including both E. faecalis and E. faecium (including vancomycin resistant strains), as well as other human pathogens.

Abstract: The present disclosure relates to methods, compositions and articles of manufacture useful for the treatment of Streptococcus pneumonia bacteria and spores, and related conditions. The disclosure further relates to methods and compositions for the identification of a phage associated lytic enzyme to rapidly kill Streptococcus pneumoniae and other bacteria. Related articles of manufacture, methods of degrading spores and methods of treatment of infections or bacteria populations of, or subjects exposed to or at risk for exposure to, Streptococcus pneumoniae are also provided.

Abstract: The present invention relates to purified multimeric proteins, comprising PlyCB monomers or functional fragments or variants thereof, which self-assemble into a ring like structure. The present invention also encompasses such multimeric proteins that comprise an integrin-binding sequence. The present invention further discloses contrast reagents, implant coatings, bone implants, and complexes for use in bionanotechnology applications, each of which comprise such multimeric proteins.

Abstract: Methods, compositions and articles of manufacture useful for the treatment of various Group B streptococci (GBS) bacteria using various lysins, including certain PlyGBS mutant lysins, are provided.

Abstract: The present disclosure relates to methods, compositions and articles of manufacture useful for the treatment of Bacillus anthracis and B. cereus bacteria and spores, and related conditions. The disclosure further relates to methods and compositions for the identification of a phage associated lytic enzyme to rapidly and specifically detect and kill Bacillus anthracis and other bacteria. Related articles of manufacture, methods of degrading spores and methods of treatment of infections or bacteria populations of, or subjects exposed to or at risk for exposure to, Bacillus anthracis are also provided.

Abstract: The full-length nucleic acid sequence of the C1 bacteriophage is disclosed in the present application. The specific regions of the C1 genome encoding the PlyC lysin have also been identified and sequenced. The invention relates to the pharmaceutical and diagnostic utility of these sequences and provides for development of pharmaceutical compositions for treating or preventing streptococcal infections in mammals, for compositions for decontamination of inanimate surfaces and for diagnosis of streptococcal infections.

Abstract: Novel bacteriophages of Bacillus anthracis, the nucleic acids of its genome, nucleic acids comprising nucleotide sequences of open reading frames (ORFs) of its genome, and polypeptides encoded by the nucleic acids, are described. Therapeutic and diagnostic compositions, methods and kits related thereto are also provided.

Abstract: A method for the prophylactic and therapeutic treatment of bacterial infections of the skin is disclosed which comprises the treatment of an individual with an effective amount of a native or altered version of a lytic enzyme produced by a bacteria infected with a bacteriophage specific for said bacteria. The lytic enzyme is selected from a group consisting of shuffled lytic enzymes, chimeric lytic enzymes, wherein the lytic enzyme is in an environment having a pH which allows for activity of said lytic enzyme; and a carrier for delivering said lytic enzyme. Additionally, a holin protein for puncturing the membrane may be included in the composition.

Abstract: The present invention identifies a new approach for antibiotic development. By identifying molecules in the cell wall of bacteria responsible for binding bacteriophage lytic enzymes, the present invention focuses on the pathways for possible antibiotic development. The pathway for the bacterial molecule is critical for bacterial survival and thus serves as a target for antibiotic identification.

Abstract: A lozenge for the treatment of Streptococcus Group A infections of the mouth, throat, and nasal passage is disclosed which comprises a lytic enzyme composition specific for Streptococcus Group A and a lozenge carrier for delivering the lytic enzyme.

Abstract: A composition and method for treating bacterial infections by the use of an effective amount of at least one lytic specific for the bacteria causing specific. The lytic enzyme is genetically coded for by a bacteriophage which may be specific for said bacteria. The enzyme may be at least one lytic protein or peptides in a natural or modified form.

Abstract: The present disclosure relates to bacteriophage lysins useful for the reduction of certain bacterial populations, including methods and compositions for the treatment of various bacterial infections. For example, bacteriophage lysins were isolated and shown to effectively kill various bacteria, including both E. faecalis and E. faecium (including vancomycin resistant strains), as well as other human pathogens.

Abstract: The present invention discloses a composition for dermatological infections by the use of a lytic enzyme in a carrier suitable for topical application to dermal tissues. The method for the treatment of dermatological infections comprises administering a composition comprising effective amount of a therapeutic agent, with the therapeutic agent comprising a lytic enzyme produced by infecting a bacteria with phage specific for that bacteria.

Abstract: A composition and method for treating bacterial infections by the use of an effective amount of at least one lytic specific for the bacteria causing specific. The lytic enzyme is genetically coded for by a bacteriophage which may be specific for said bacteria. The enzyme may be at least one lytic protein or peptides in a natural or modified form.

Abstract: The present invention relates to an oral delivery system containing a bacteriophage associated lysin enzyme for the treatment of [Streptococcus pneumoniae and] Hemophilus influenzae sinus/nasal infections.

Abstract: Methods for treating and preventing bacterial infections are described using at least two lytic enzymes obtained from a bacteriophage isolated from Streptococci. Two of these enzymes, Pal and Cpl-1, showed synergy when tested for cleavage of peptidoglycan in the cell walls of Streptococcus pneumoniae. Moreover, the combination of these two enzymes resulted in killing of both penicillin sensitive as well as penicillin resistant strains of S. pneumoniae. The synergy displayed by the combined use of these two enzymes may establish a means for identification of agents that mimic or enhance this activity and may lead to the identification of new antimicrobial agents and pharmaceutical compositions useful for treating and preventing a variety of bacterial infections in mammals. Further compositions are described for disinfecting or sanitizing porous and non-porous surfaces suspected of harboring infectious organisms.